This is not the most recent version of the article. View current version (31 MAR 2014)

Intervention Protocol

Darbepoetin for the anaemia of chronic kidney disease

  1. Sankar D Navaneethan1,
  2. Suetonia C Palmer2,
  3. Jonathan C Craig3,
  4. Giovanni FM Strippoli3,4,5,*

Editorial Group: Cochrane Renal Group

Published Online: 7 SEP 2011

DOI: 10.1002/14651858.CD009297


How to Cite

Navaneethan SD, Palmer SC, Craig JC, Strippoli GFM. Darbepoetin for the anaemia of chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 9. Art. No.: CD009297. DOI: 10.1002/14651858.CD009297.

Author Information

  1. 1

    Glickman Urological and Kidney institute, Cleveland Clinic, Department of Nephrology and Hypertension, Cleveland, OH, USA

  2. 2

    University of Otago Christchurch, Department of Medicine, Christchurch, New Zealand

  3. 3

    University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia

  4. 4

    Mario Negri Sud Consortium, Santa Maria Imbaro (Ch), Italy

  5. 5

    Diaverum Medical-Scientific Office, Lund, Sweden

*Giovanni FM Strippoli, Giovanni.Strippoli@diaverum.com. strippoli@negrisud.it.

Publication History

  1. Publication Status: New
  2. Published Online: 7 SEP 2011

SEARCH

This is not the most recent version of the article. View current version (31 MAR 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

We will evaluate the benefits and harms of darbepoetin alpha compared with other ESAs, placebo, or no treatment in individuals with CKD.